Low podoplanin expression of tumor cells predicts poor prognosis in pathological stage IB squamous cell carcinoma of the lung, tissue microarray analysis of 136 patients using 24 antibodies

被引:46
作者
Ito, Takeo [1 ,2 ]
Ishii, Genichiro [1 ]
Nagai, Kanji [2 ]
Nagano, Tatsuya [1 ,2 ]
Kojika, Masakazu [1 ,2 ]
Murata, Yukinori [1 ]
Atsumi, Naho [1 ]
Nishiwaki, Yutaka [2 ]
Miyazaki, Eishi [3 ]
Kumamoto, Toshihide [4 ]
Ochiai, Atsushi [1 ]
机构
[1] Natl Canc Ctr Hosp E, Div Pathol, Res Ctr Innovat Oncol, Chiba, Japan
[2] Natl Canc Ctr Hosp E, Thorac Oncol Div, Chiba, Japan
[3] Oita Univ, Fac Med, Div Pulm Dis, Dept Brain & Nerve Sci, Oita 87011, Japan
[4] Oita Univ, Fac Med, Div Neurol & Neuromuscular Disorders, Dept Brain & Nerve Sci, Oita 87011, Japan
关键词
Stage IB; Squamous cell carcinoma; Lung cancer; Prognosis; Podoplanin; D2-40; Tissue microarray; Immunchistochemistry; AGGREGATION-INDUCING FACTOR; VINORELBINE PLUS CISPLATIN; PHASE-II TRIAL; ADJUVANT CHEMOTHERAPY; CANCER; ASSOCIATION; METASTASIS; GEFITINIB; INVASION; TEGAFUR;
D O I
10.1016/j.lungcan.2008.06.008
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The aim of this study was to identify clinicopathological and biological prognostic markers for patients who had undergone complete resection of pathological stage IB squamous cell carcinoma (SqCC) of the lung. A total of 136 consecutive stage IB SqCC patients fulfilled eligibility criteria, and their clinicopathological factors were evaluated. Tissue microarrays were also constracted, and immunohistochemical staining with 24 antibodies was performed. Correlations between clinicopathological factors, antibody immunohistochernical reactions, the patients' over all survival (OS) and relapse-free survival (RFS) were evaluated. The univariate analysis showed that 70-year-old and over elderly group had a shorter OS time and RFS time than the younger group (p=0.0086 and p=0.0091, respectively). The univariate analysis for immunohistochernical staining showed that the podoplanin-negative group had a shorter OS time and RFS time than the podoplanin-positive group (p=0.0106 and p=0.0308, respectively). Multivariate analysis revealed a significant correlation between both the 70-year-old and over elderly group and the podoplanin-negative group and poor outcome (OS, p=0.007 and p=0.008, respectively; RFS, p=0.008 and p=0.024, respectively). The results showed that patient age and a novel biological prognostic marker, podoplanin, are useful for predicting a poor outcome of patients after complete resection of stage IB SqCC of the lung. (c) 2008 Elsevier Ireland Ltd. All rights reserved.
引用
收藏
页码:418 / 424
页数:7
相关论文
共 25 条
[1]   Gefitinib (IRESSA) in patients of Asian origin with refractory advanced non-small cell lung cancer: Subset analysis from the ISEL study [J].
Chang, Alex ;
Parikh, Purvish ;
Thongprasert, Sumitra ;
Tan, Eng Huat ;
Perng, Reury- Perng ;
Ganzon, Domingo ;
Yang, Chih-Hsin ;
Tsao, Chao-Jung ;
Watkins, Claire ;
Botwood, Nick ;
Thatcher, Nick .
JOURNAL OF THORACIC ONCOLOGY, 2006, 1 (08) :847-855
[2]   Adjuvant vinorelbine plus cisplatin versus observation in patients with completely resected stage IB-IIIA non-small-cell lung cancer (Adjuvant Navelbine International Trialist Association [ANITA]):: a randomised controlled trial [J].
Douillard, Jean-Yves ;
Rosell, Rafael ;
De Lena, Mario ;
Carpagnano, Francesco ;
Ramlau, Rodryg ;
Gonzales-Larriba, Jose Luis ;
Grodzki, Tornasz ;
Pereira, Jose Rodrigues ;
Le Groumellec, Alain ;
Lorusso, Vito ;
Clary, Claude ;
Torres, Antonio J. ;
Dahabreh, Jabrail ;
Souquet, Pierre-Jean ;
Astudillo, Julio ;
Fournel, Pierre ;
Artal-Cortes, Angel ;
Jassem, Jacek ;
Koubkova, Leona ;
His, Patricia ;
Riggi, Marcella ;
Hurteloup, Patrick .
LANCET ONCOLOGY, 2006, 7 (09) :719-727
[3]   Low D2-40 immunoreactivity correlates with lymphatic invasion and nodal metastasis in early-stage squamous cell carcinoma of the uterine cervix [J].
Dumoff, KL ;
Chu, C ;
Xu, XW ;
Pasha, T ;
Zhang, PJ ;
Acs, G .
MODERN PATHOLOGY, 2005, 18 (01) :97-104
[4]   Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer [J].
Fukuoka, M ;
Yano, S ;
Giaccone, G ;
Tamura, T ;
Nakagawa, K ;
Douillard, JY ;
Nishiwaki, Y ;
Vansteenkiste, J ;
Kudoh, S ;
Rischin, D ;
Eek, R ;
Horai, T ;
Noda, K ;
Takata, I ;
Smit, E ;
Averbuch, S ;
Macleod, A ;
Feyereislova, A ;
Dong, RP ;
Baselga, J .
JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (12) :2237-2246
[5]   Clinicopathologic characteristics of peripheral squamous cell carcinoma of the lung [J].
Funai, K ;
Yokose, T ;
Ishii, G ;
Araki, K ;
Yoshida, J ;
Nishimura, M ;
Nagai, K ;
Nishiwaki, Y ;
Ochiai, A .
AMERICAN JOURNAL OF SURGICAL PATHOLOGY, 2003, 27 (07) :978-984
[6]  
Giatromanolaki A, 2001, CANCER RES, V61, P7992
[7]   Prognosis of 6644 resected non-small cell lung cancers in Japan: A Japanese lung cancer registry study [J].
Goya, T ;
Asamura, H ;
Yoshimura, H ;
Kato, H ;
Shimokata, K ;
Tsuchiya, R ;
Sohara, Y ;
Miya, T ;
Miyaoka, E .
LUNG CANCER, 2005, 50 (02) :227-234
[8]   Meta-analysis of postoperative adjuvant chemotherapy with tegafur-uracil in non-small-cell lung cancer [J].
Hamada, C ;
Tanaka, F ;
Ohta, M ;
Fujimura, S ;
Kodama, K ;
Imaizumi, M ;
Wada, H .
JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (22) :4999-5006
[9]   Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer [J].
Johnson, DH ;
Fehrenbacher, L ;
Novotny, WF ;
Herbst, RS ;
Nemunaitis, JJ ;
Jablons, DM ;
Langer, CJ ;
DeVore, RF ;
Gaudreault, J ;
Damico, LA ;
Holmgren, E ;
Kabbinavar, F .
JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (11) :2184-2191
[10]   A randomized trial of adjuvant chemotherapy with uracil-tegafur for adenocarcinoma of the lung [J].
Kato, H ;
Ichinose, Y ;
Ohta, M ;
Hata, E ;
Tsubota, N ;
Tada, H ;
Watanabe, Y ;
Wada, H ;
Tsuboi, M ;
Hamajima, N ;
Ohta, M .
NEW ENGLAND JOURNAL OF MEDICINE, 2004, 350 (17) :1713-1721